Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users.
A cohort of 334 intravenous (IV) drug users from New York City drug treatment programs were followed over a mean 9-month period. Among the 165 who were seropositive at enlistment, four developed clinical AIDS, for an annual rate of 3%. Elevated IgA was a significant predictor of developing AIDS. Among 72 subjects who were initially seronegative and who were re-interviewed, four were seropositive at follow-up, for a seroconversion rate of 7% per year among seronegatives. Among seropositive subjects who did not develop AIDS or fatal AIDS related complex (ARC), continued drug injection was associated with rate of T4 cell loss, and there was a non-significant trend for males to lose T4 cells more rapidly than females. While it was not possible to distinguish the mechanism underlying the relationship between continued drug injection and T4 cell loss, seropositive IV drug users should be warned that continued injection may lead to increased HIV-related immunosuppression as well as, if injection equipment is shared, risking viral transmission to others.
D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology; D000914:Antibodies, Viral / Q000096:biosynthesis; D004812:Epidemiologic Methods; D005260:Female; D006678:HIV / Q000276:immunology; D015483:HIV Antibodies; D006801:Humans; D007108:Immune Tolerance; D007275:Injections, Intravenous / Q000009:adverse effects; D008297:Male; D009519:New York City; D019966:Substance-Related Disorders / Q000150:complications* / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D000914:Antibodies, Viral; D015483:HIV Antibodies